The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

The Phase 2 trial, called ANDROMEDA, is the first study to directly compare two types of PSMA-targeted radiopharmaceuticals when used alongside stereotactic body radiotherapy (SBRT), a focused form of ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...

Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers. Two-thirds of patients were alive at 2 years with minimal serious toxicity ...

A former prostate cancer patient who got the all-clear said taking part in a trial that cut his radiotherapy treatments ...

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before the cancer comes back. Researchers at UCLA have found that a blend of a ...

Phase III trial presented at ASTRO in San Francisco finds five-treatment regimen poised to become new standard of care. The principal investigator of the trial, Ellis is a radiation oncologist and ...

Stereotactic body radiotherapy (SBRT) alone achieves a 69.7% pooled 1- or 2-year systemic therapy-free survival rate across cancer types, with the highest rates seen in renal cell and prostate cancers ...

Acute bowel symptoms following relugolix and stereotactic body radiotherapy for localized prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

MiraDx Announces the Commercial Availability of PROSTOX™ ultra for Prediction of Risk of Late Genitourinary Toxicity in Prostate Cancer Patients Considering Radiation Therapy MiraDx, a molecular ...